limbal stem cells deficiency epidemiology forecast

DelveInsight’s ‘Limbal Stem Cell Deficiency (LSCD) – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of Limbal Stem Cell Deficiency (LSCD) historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan, and South Korea.

Geographies Covered

• The United States
• The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• South Korea

Study Period: 2021-2034

Limbal Stem Cell Deficiency (LSCD) Disease Understanding

LSCD is an ocular surface disease caused by a decrease in the population and function of corneal epithelial stem/progenitor cells; this decrease leads to the inability to sustain the normal homeostasis of the corneal epithelium. The disease is characterized by conjunctivalization (i.e., replacement of the normal corneal epithelium by conjunctival epithelium) and/or other signs of epithelial dysfunction such as persistent or recurrent epithelial defects with or without neovascularization, ocular surface inflammation, and scarring.

Patients suffering from LSCD may present symptoms related to poor epithelial wound healing and recurrent erosions. Patients often experience chronic conjunctival redness, decreased vision, photophobia, foreign body sensation, tearing, blepharospasm, and recurrent episodes of pain from recurrent epithelial breakdown. The pain, photophobia, and discomfort are often debilitating. However, most of these symptoms are nonspecific and inadequate to diagnose correctly.

Limbal Stem Cell Deficiency (LSCD) Epidemiology

The limbal stem cell deficiency (LSCD) epidemiology report provides insights into the historical and incident patient pool and the forecasted trend for all seven major countries and South Korea. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The total diagnosed prevalent cases of limbal stem cell deficiency (LSCD) patients in the 7MM + South Korea will increase during the study period, i.e., 2021-2034.

The disease epidemiology covered in the report provides historical as well as forecasted limbal stem cell deficiency (LSCD) symptoms epidemiology segmented as the total diagnosed prevalent cases of limbal stem cell deficiency (LSCD), severity-specific diagnosed cases of limbal stem cell deficiency (LSCD), gender-specific diagnosed cases of limbal stem cell deficiency (LSCD), type-specific diagnosed cases of limbal stem cell deficiency (LSCD), and cause-specific diagnosed cases of limbal stem cell deficiency (LSCD). The report includes the diagnosed prevalent cases scenario of limbal stem cell deficiency (LSCD) in the 7MM + South Korea covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and South Korea from 2021 to 2034.

Country-wise Limbal Stem Cell Deficiency (LSCD) Epidemiology

The epidemiology segment also provides the Limbal Stem Cell Deficiency (LSCD) epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and South Korea.

• The diagnosed prevalent cases of Limbal Stem Cell Deficiency (LSCD) associated with the 7MM + South Korea were around 250,000 in 2021.
• As per the estimates, the United States had the highest number of diagnosed prevalent cases of limbal stem cell deficiency (LSCD) in 2021.
• Among the EU5 countries, Germany had the highest number of diagnosed prevalent cases of limbal stem cell deficiency (LSCD), followed by France in 2021. On the other hand, Spain had the lowest number of diagnosed prevalent cases, with around 14,000 cases in 2021.
• The diagnosed prevalent cases of Limbal Stem Cell Deficiency (LSCD) in Japan was approximately 38,000 in 2021, while in South Korea, the number of diagnosed prevalent cases was ~16,000.

Scope of the Report

• The Limbal Stem Cell Deficiency (LSCD) Report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The Limbal Stem Cell Deficiency (LSCD) Epidemiology Report and Model provide an overview of Limbal Stem Cell Deficiency (LSCD)’s risk factors and global trends in the seven major markets (the 7MM: US, France, Germany, Italy, Spain, the UK, and Japan) and South Korea.
• The report provides insight into Limbal Stem Cell Deficiency (LSCD)’s historical and forecasted patient pool in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, the UK), Japan, and South Korea.
• The report helps to recognize the growth opportunities in the 7MM + South Korea concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Limbal Stem Cell Deficiency (LSCD).
• The report provides the segmentation of Limbal Stem Cell Deficiency (LSCD) epidemiology by the diagnosed prevalent cases of limbal stem cell deficiency (LSCD) in 7MM + South Korea.
• The report provides the Limbal Stem Cell Deficiency (LSCD) epidemiology segmentation by type-specific cases of limbal stem cell deficiency (LSCD) in 7MM + South Korea.
• The report provides the Limbal Stem Cell Deficiency (LSCD) epidemiology segmentation by severity-specific cases of limbal stem cell deficiency (LSCD) in 7MM + South Korea.
• The report provides the Limbal Stem Cell Deficiency (LSCD) epidemiology segmentation by gender-specific cases of limbal stem cell deficiency (LSCD) in 7MM + South Korea.
• The report provides the limbal stem cell deficiency (LSCD) epidemiology segmentation by cause-specific cases of limbal stem cell deficiency (LSCD) in 7MM+ South Korea.

Report Highlights

• 10-year forecast of Limbal Stem Cell Deficiency (LSCD) Epidemiology
• The 7MM + South Korea Coverage
• Total Diagnosed Prevalent Cases of Limbal Stem Cell Deficiency (LSCD)
• Severity-specific Diagnosed Cases of Limbal Stem Cell Deficiency (LSCD)
• Gender-specific Diagnosed Cases of Limbal Stem Cell Deficiency (LSCD)
• Type-specific Diagnosed Cases of Limbal Stem Cell Deficiency (LSCD)
• Cause-specific Diagnosed Cases of Limbal Stem Cell Deficiency (LSCD)

KOL Views

We interview KOLs, and SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

• What major factors will drive the change in the patient population in Limbal Stem Cell Deficiency (LSCD) during the forecast period (2025-2034)?
• What are the key findings of Limbal Stem Cell Deficiency (LSCD) epidemiology across the 7MM + South Korea, and which country will have the highest number of patients during the forecast period (2025-2034)?
• What would be the total number of Limbal Stem Cell Deficiency (LSCD) patients across the 7MM + South Korea forecast period (2025-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow in 7MM + South Korea during the forecast period (2025-2034)?
• What are the disease risks, burdens, and unmet needs of the Limbal Stem Cell Deficiency (LSCD) market?
• What are the current treatment patterns for Limbal Stem Cell Deficiency (LSCD)?

Reasons to buy

The Limbal Stem Cell Deficiency (LSCD) epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Limbal Stem Cell Deficiency (LSCD) market.
• Quantify patient populations in the global Limbal Stem Cell Deficiency (LSCD) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Limbal Stem Cell Deficiency (LSCD) therapeutics in each market covered.
• Understand the magnitude of the Limbal Stem Cell Deficiency (LSCD) population by its diagnosed prevalence.
• Understand the magnitude of the Limbal Stem Cell Deficiency (LSCD) population by its type-specific, severity-specific, gender-specific, and cause-specific cases.
• The Limbal Stem Cell Deficiency (LSCD) Epidemiology Report and model were written and developed by Master's and Ph.D. level epidemiologists.
• The Limbal Stem Cell Deficiency (LSCD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources.

Key Assessments

• Patient segmentation
• Disease risk and burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population